These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30728774)

  • 21. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hotspot mutations delineating diverse mutational signatures and biological utilities across cancer types.
    Chen T; Wang Z; Zhou W; Chong Z; Meric-Bernstam F; Mills GB; Chen K
    BMC Genomics; 2016 Jun; 17 Suppl 2(Suppl 2):394. PubMed ID: 27356755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiscale mutation clustering algorithm identifies pan-cancer mutational clusters associated with pathway-level changes in gene expression.
    Poole W; Leinonen K; Shmulevich I; Knijnenburg TA; Bernard B
    PLoS Comput Biol; 2017 Feb; 13(2):e1005347. PubMed ID: 28170390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of PanDrugs to prioritize anticancer drug treatments in a case of T-ALL based on individual genomic data.
    Fernández-Navarro P; López-Nieva P; Piñeiro-Yañez E; Carreño-Tarragona G; Martinez-López J; Sánchez Pérez R; Aroca Á; Al-Shahrour F; Cobos-Fernández MÁ; Fernández-Piqueras J
    BMC Cancer; 2019 Oct; 19(1):1005. PubMed ID: 31655559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA methyltransferases as targets for cancer therapy.
    Ghoshal K; Bai S
    Drugs Today (Barc); 2007 Jun; 43(6):395-422. PubMed ID: 17612710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging biological therapies for the treatment of myelodysplastic syndromes.
    Zeidan AM; Stahl M; Komrokji R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):283-300. PubMed ID: 27486848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation.
    Mashima T; Ushijima M; Matsuura M; Tsukahara S; Kunimasa K; Furuno A; Saito S; Kitamura M; Soma-Nagae T; Seimiya H; Dan S; Yamori T; Tomida A
    Cancer Sci; 2015 Jul; 106(7):909-20. PubMed ID: 25911996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-Throughput Mutation Data Now Complement Transcriptomic Profiling: Advances in Molecular Pathway Activation Analysis Approach in Cancer Biology.
    Buzdin A; Sorokin M; Poddubskaya E; Borisov N
    Cancer Inform; 2019; 18():1176935119838844. PubMed ID: 30936679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune and Stroma Related Genes in Breast Cancer: A Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database.
    Xu M; Li Y; Li W; Zhao Q; Zhang Q; Le K; Huang Z; Yi P
    Front Med (Lausanne); 2020; 7():64. PubMed ID: 32195260
    [No Abstract]   [Full Text] [Related]  

  • 31. Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer.
    Li X; Pasche B; Zhang W; Chen K
    JAMA Oncol; 2018 Dec; 4(12):1691-1698. PubMed ID: 30098163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes.
    Liu C; Zhao J; Lu W; Dai Y; Hockings J; Zhou Y; Nussinov R; Eng C; Cheng F
    PLoS Comput Biol; 2020 Feb; 16(2):e1007701. PubMed ID: 32101536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure.
    Tokheim C; Bhattacharya R; Niknafs N; Gygax DM; Kim R; Ryan M; Masica DL; Karchin R
    Cancer Res; 2016 Jul; 76(13):3719-31. PubMed ID: 27197156
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A bioinformatics approach for precision medicine off-label drug drug selection among triple negative breast cancer patients.
    Cheng L; Schneider BP; Li L
    J Am Med Inform Assoc; 2016 Jul; 23(4):741-9. PubMed ID: 27107440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COSMIC: somatic cancer genetics at high-resolution.
    Forbes SA; Beare D; Boutselakis H; Bamford S; Bindal N; Tate J; Cole CG; Ward S; Dawson E; Ponting L; Stefancsik R; Harsha B; Kok CY; Jia M; Jubb H; Sondka Z; Thompson S; De T; Campbell PJ
    Nucleic Acids Res; 2017 Jan; 45(D1):D777-D783. PubMed ID: 27899578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncobox Bioinformatical Platform for Selecting Potentially Effective Combinations of Target Cancer Drugs Using High-Throughput Gene Expression Data.
    Sorokin M; Kholodenko R; Suntsova M; Malakhova G; Garazha A; Kholodenko I; Poddubskaya E; Lantsov D; Stilidi I; Arhiri P; Osipov A; Buzdin A
    Cancers (Basel); 2018 Sep; 10(10):. PubMed ID: 30274248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CCG: an integrative resource of cancer protein-coding genes and long noncoding RNAs.
    Liu M; Yang YT; Xu G; Tan C; Lu ZJ
    Discov Med; 2016 Dec; 22(123):351-359. PubMed ID: 28147217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
    Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
    Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.